No connection

Search Results

AIDX

BEARISH
$1.91 Live
20/20 Biolabs, Inc. · NASDAQ
$1.51 52W Range $50.0

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 08, 2026
Market cap
$19.95M
P/E
N/A
ROE
-503.1%
Profit margin
-182.8%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
60%
AIDX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.

Key Strengths

Company has established market presence

Key Risks

Low profit margin of -182.8%
Weak financial trend (Piotroski F-Score: 3/9)
Weak ROE of -503.1%

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
32
Weak
Value
50
Future
50
Past
30
Health
30
Dividend
0
AI Verdict
AIDX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -182.8%, Weak financial trend (Piotroski F-Score: 3/9)
Confidence
20%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
50/100

Rule-based growth outlook.

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
30/100

Historical performance + price trend: Shares moved -92.0% over 5Y and -92.0% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -503.1%.
  • Thin profit margins.
Health
30/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.91

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for AIDX and closest competitors.

Updated 2026-04-07
AID
20/20 Biolabs, Inc.
Primary
5Y
-92.0%
3Y
-92.0%
1Y
-92.0%
6M
-92.0%
1M
-32.8%
1W
+1.6%
BMG
Basel Medical Group Ltd
Peer
5Y
-82.0%
3Y
-82.0%
1Y
-82.0%
6M
-64.4%
1M
+23.8%
1W
-3.5%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
BNG
Bionano Genomics, Inc.
Peer
5Y
-100.0%
3Y
-99.8%
1Y
-64.6%
6M
-35.8%
1M
+0.9%
1W
+3.6%
BTA
BioXcel Therapeutics, Inc.
Peer
5Y
-99.8%
3Y
-99.6%
1Y
-30.1%
6M
-56.4%
1M
-37.0%
1W
-18.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
159.17
P/S Ratio
9.75
EV/Revenue
10.5
EV/EBITDA
-6.62
Market Cap
$19.95M

Profitability

Profit margins and return metrics

Profit Margin -182.82%
Operating Margin -169.59%
Gross Margin 29.56%
ROE -503.12%
ROA -53.92%

Growth

Revenue and earnings growth rates

Revenue Growth +0.4%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.6
Weak
Quick Ratio
0.5
Poor
Cash/Share
$0.1

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
24.2%
Op. Margin
-169.6%
Net Margin
-243.0%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$-0.0B
Debt/Equity
-216.21x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Healthcare Sector Comparison

Comparing AIDX against 162 companies in the Healthcare sector (15 bullish, 52 neutral, 95 bearish)
Return on Equity (ROE)
-503.12%
This Stock
vs
-42.35%
Sector Avg
+1087.9% (Excellent)
Profit Margin
-182.82%
This Stock
vs
-18.25%
Sector Avg
+902.0% (Superior)
Revenue Growth
0.4%
This Stock
vs
114.26%
Sector Avg
-99.6% (Slower)
Current Ratio
0.6
This Stock
vs
3.36
Sector Avg
-82.2% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning AIDX from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile